Dr. Michael Vaezi, MD, PHD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- University of Alabama School of Medicine (1992)
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 243
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1992Medical school: University of Alabama School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
TN license MD40379
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Vanderbilt University Medical Center Nashville, TN
Medical groups
- Vanderbilt University Medical Center (3,567 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 243
- Services billed
- 556
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 154 | 114 |
| Dilation of esophagus | 144 | 101 |
| Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | 143 | 85 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 82 | 77 |
| Established patient office or other outpatient visit, 10-19 minutes | 46 | 46 |
| Study of esophagus to assess movement | 31 | 31 |
| New patient office or other outpatient visit, 30-44 minutes | 30 | 30 |
| Monitoring and recording of esophageal function through a capsule attached to the esophagus wall | 21 | 21 |
| Established patient office or other outpatient visit, 20-29 minutes | 18 | 18 |
| Biopsy of large bowel using a flexible endoscope | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Omeprazole Other prescribers in Nashville, TN | 94 |
| Famotidine Other prescribers in Nashville, TN | 53 |
| Pantoprazole Sodium Other prescribers in Nashville, TN | 32 |
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Nashville, TN | 22 |
| Dexlansoprazole Dr (dexlansoprazole) Other prescribers in Nashville, TN | 18 |
| Ondansetron Hcl Other prescribers in Nashville, TN | 15 |
| Dicyclomine Hcl Other prescribers in Nashville, TN | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $85,231 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis.
Celgene Corporation - A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis.
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.